STOCK TITAN
  1. Home
  2. Sec-filings
  3. NRSN
  4. [EFFECT] NeuroSense Therapeutics Ltd. SEC Filing

[EFFECT] NeuroSense Therapeutics Ltd. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: November 25, 2025 4:00 P.M.
Form: F-3
CIK: 0001875091
Company Name: NeuroSense Therapeutics Ltd.
File Number: 333-291122

Source: View Original Filing on SEC EDGAR

Neurosense Therapeutics Ltd

NASDAQ:NRSN

View NRSN Stock Overview →

NRSN Rankings

#5938 Ranked by Market Cap
N/A Ranked by Dividends

NRSN Latest News

Mar 9, 2026
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
Feb 18, 2026
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
Feb 9, 2026
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
Jan 21, 2026
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
Jan 8, 2026
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB

NRSN Latest SEC Filings

Mar 11, 2026
[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer)
Feb 18, 2026
[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer)
Feb 13, 2026
[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer)
Feb 9, 2026
[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer)
Jan 29, 2026
[F-3] NeuroSense Therapeutics Ltd. Foreign Issuer Shelf Registration

NRSN Stock Data

29.00M
27.00M
Biotechnology
Healthcare
Link
Israel
Herzliya